Chris Cameron

14.0k total citations · 3 hit papers
86 papers, 9.4k citations indexed

About

Chris Cameron is a scholar working on Hematology, Pathology and Forensic Medicine and Economics and Econometrics. According to data from OpenAlex, Chris Cameron has authored 86 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 15 papers in Pathology and Forensic Medicine and 11 papers in Economics and Econometrics. Recurrent topics in Chris Cameron's work include Health Systems, Economic Evaluations, Quality of Life (11 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Meta-analysis and systematic reviews (9 papers). Chris Cameron is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (11 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Meta-analysis and systematic reviews (9 papers). Chris Cameron collaborates with scholars based in Canada, United States and Germany. Chris Cameron's co-authors include Brian Hutton, David Moher, Ferrán Catalá-López, Sharon E. Straus, Jeroen P. Jansen, Cynthia D. Mulrow, John P. A. Ioannidis, Kristian Thorlund, Isabelle Boutron and Deborah M Caldwell and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Chris Cameron

85 papers receiving 9.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

2015 5.7k citations Brian Hutton, Chris Cameron et al. profile →
Prolonged operative duration is associated with complications: a systematic review and meta-analysis

2018 522 citations Nicole Ferko, Chris Cameron et al. profile →
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

2015 441 citations Chris Cameron, Doug Coyle et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Chris Cameron	2.1k	1.5k	1.2k	1.1k	957	86	9.4k
Sofia Dias	1.5k 0.7×	1.4k 0.9×	1.3k 1.1×	1.0k 0.9×	761 0.8×	170	11.2k
Jeroen P. Jansen	2.1k 1.0×	1.0k 0.7×	1.7k 1.4×	1.4k 1.3×	1.3k 1.4×	146	12.1k
Lucas M. Bachmann	1.8k 0.9×	1.1k 0.8×	1.6k 1.3×	1.4k 1.3×	591 0.6×	229	11.3k
George Divine	1.8k 0.8×	1.2k 0.8×	1.1k 0.9×	1.3k 1.1×	1.0k 1.1×	226	9.7k
Ferrán Catalá-López	1.5k 0.7×	934 0.6×	997 0.8×	1.0k 0.9×	701 0.7×	127	8.9k
Ammarin Thakkinstian	1.7k 0.8×	1.1k 0.7×	781 0.6×	1.4k 1.3×	794 0.8×	351	10.0k
Iztok Hozo	3.0k 1.4×	911 0.6×	1.5k 1.2×	1.0k 0.9×	1.1k 1.1×	98	9.0k
Shelley Hurwitz	1.4k 0.7×	1.1k 0.7×	928 0.7×	942 0.8×	590 0.6×	160	7.8k
Joel Singer	2.4k 1.1×	1.8k 1.2×	1.3k 1.0×	2.1k 1.9×	444 0.5×	141	12.0k
Xinjun Li	1.3k 0.6×	923 0.6×	1.1k 0.9×	1.9k 1.7×	1.8k 1.9×	366	9.6k

Countries citing papers authored by Chris Cameron

Since Specialization

Citations

This map shows the geographic impact of Chris Cameron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Cameron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Cameron more than expected).

Fields of papers citing papers by Chris Cameron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Cameron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Cameron. The network helps show where Chris Cameron may publish in the future.

Co-authorship network of co-authors of Chris Cameron

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Cameron. A scholar is included among the top collaborators of Chris Cameron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Cameron. Chris Cameron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Seddon, Mary, et al.. (2025). The Adverse Drug Event Collaborative: a joint venture to measure medication-related patient harm. PubMed. 126(1368). 9–20.

Buckstein, Rena, Karen Yee, Michelle Geddes, et al.. (2023). The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma. 64(3). 651–661. 3 indexed citations

Martin, Tom, Saad Z. Usmani, Jordan M. Schecter, et al.. (2021). Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion. 37(10). 1779–1788. 34 indexed citations

Law, Ernest H., et al.. (2021). Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. Journal of Comparative Effectiveness Research. 11(2). 109–120. 5 indexed citations

Harbeck, Nadia, Dean Spurden, Lin Zhan, et al.. (2021). CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies. Future Oncology. 17(16). 2107–2122. 51 indexed citations

Samjoo, Imtiaz A., Evelyn Worthington, Melody Zhao, et al.. (2021). Efficacy classification of modern therapies in multiple sclerosis. Journal of Comparative Effectiveness Research. 10(6). 495–507. 80 indexed citations

Samjoo, Imtiaz A., et al.. (2021). Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Current Medical Research and Opinion. 37(11). 1933–1944. 4 indexed citations

Law, Ernest H., et al.. (2021). Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. The Breast. 57. 5–17. 40 indexed citations

Rugo, Hope S., Lin Zhan, Anh N. Tran, et al.. (2021). Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer. Journal of Comparative Effectiveness Research. 10(6). 457–467. 11 indexed citations

10.

Samjoo, Imtiaz A., Evelyn Worthington, Chris Cameron, et al.. (2020). Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Current Medical Research and Opinion. 36(7). 1157–1166. 13 indexed citations

11.

Samjoo, Imtiaz A., Evelyn Worthington, Chris Cameron, et al.. (2020). The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. Current Medical Research and Opinion. 36(7). 1145–1156. 5 indexed citations

12.

Samjoo, Imtiaz A., Evelyn Worthington, Melody Zhao, et al.. (2020). Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of Comparative Effectiveness Research. 9(18). 1255–1274. 45 indexed citations

13.

Samjoo, Imtiaz A., et al.. (2020). The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy. Current Medical Research and Opinion. 36(5). 799–808. 4 indexed citations

14.

Cameron, Chris, et al.. (2019). Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis. BMC Medical Research Methodology. 19(1). 193–193. 2 indexed citations

15.

Coombes, Megan, et al.. (2018). Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Systematic Reviews. 7(1). 191–191. 28 indexed citations

16.

Disher, Timothy, et al.. (2018). Pain-Relieving Interventions for Retinopathy of Prematurity: A Meta-analysis. PEDIATRICS. 142(1). 36 indexed citations

17.

Zigler, Jack E., Matthew F. Gornet, Nicole Ferko, et al.. (2017). Comparison of Lumbar Total Disc Replacement With Surgical Spinal Fusion for the Treatment of Single-Level Degenerative Disc Disease: A Meta-Analysis of 5-Year Outcomes From Randomized Controlled Trials. Global Spine Journal. 8(4). 413–423. 48 indexed citations

18.

Mitra, Debanjali, et al.. (2017). Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Research and Treatment. 166(1). 167–177. 29 indexed citations

19.

Caulley, Lisa, Kednapa Thavorn, Luke Rudmik, Chris Cameron, & Shaun Kilty. (2015). Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: Results of the US Medical Expenditure Panel Survey. Journal of Allergy and Clinical Immunology. 136(6). 1517–1522. 144 indexed citations

20.

Cameron, Chris, Doug Coyle, Trevor Richter, et al.. (2014). Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 4(6). e004301–e004301. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact